|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 3,646,207: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 3,646,207?
U.S. Patent 3,646,207 (filed in 1970 and granted in 1972) covers a class of pharmaceutical compounds, specifically 3,4-benzodiazepines. The patent claims a series of compounds with the general formula where the benzodiazepine ring is substituted with specific groups at designated positions, and their utility as anti-anxiety agents.
The core compound disclosed is diazepam, a widely used anxiolytic. The patent broadly claims:
- The benzodiazepine compounds described by the general formula.
- Variations with different substituents at key positions.
- The method of using these compounds as sedatives and tranquilizers.
This scope encompasses both the chemical structures and therapeutic uses, providing tactical coverage for a broad class of benzodiazepines.
What are the key claims?
Principal Claims
-
Chemical Structure: Claims covering the compounds with the general formula:
( \text{[chemical structure]} ) where R1 and R2 represent various possible substituents, such as halogens, alkyl groups, or phenyl groups, at specified positions on the benzodiazepine ring.
-
Utility: Claims asserting the compounds' use as tranquilizers, sedatives, and anti-anxiety agents, including methods of manufacture and pharmaceutical compositions.
-
Substituent Variations: Claims covering specific substitutions at R1 and R2, including compounds closely related to diazepam, meprobamate, and chlordiazepoxide.
Notable Claim Aspects
- The broadest claim (claim 1) centers on the general structure and its variants.
- Subsequent claims narrow focus to particular substituents and specific compounds exemplified in the patent.
- The claims extend to the pharmaceutical compositions and methods of treatment using the compounds.
Scope Limitations
- The claims are limited to compounds with certain substitution patterns and specific pharmacological properties.
- The patent does not cover all benzodiazepines beyond the specified structural scope.
- It excludes some later-developed benzodiazepines with different core structures or substitutions.
What does the patent landscape look like?
Patent Family and Related Patents
- U.S. Patent 3,646,207 belongs to a family with foreign counterparts, including filings in Europe (EP), Canada (CA), and other jurisdictions.
- Key related patents include other early benzodiazepine patents, such as U.S. Patent 3,584,126 (Chloradiazepoxide), and subsequent filings covering derivative compounds and formulations.
Patent Expiry and Patent Lifecycle
- The patent was filed in 1970, granted in 1972, and typically had a 17-year term at that time, expiring around 1989.
- Patent protection expired decades ago, leading to open generic competition.
- Current patent landscape around benzodiazepines mainly involves newer formulations, delivery systems, or chemical derivatives.
Patent Landscape for Benzodiazepines
- The early benzodiazepines such as diazepam (Valium), chlordiazepoxide, and lorazepam dominated patent activity from the 1960s through the 1980s.
- Several patents have overlapping claims, but most expired, creating a patent cliff.
- Modern benzodiazepine patents focus on novel formulations, delivery mechanisms, or prodrugs to extend market exclusivity.
Notable Patent Activities Post-Expiration
- Companies have filed new patents on extended-release formulations, combination therapies, or specific synthesis methods.
- Patent filings are sparse for new benzodiazepine compounds due to limited innovation in the core chemical class post-1980s.
Summary table of key data points
| Aspect |
Data |
| Patent number |
3,646,207 |
| Filing date |
January 14, 1970 |
| Issue date |
March 21, 1972 |
| Expiry date |
March 21, 1989 |
| Chemical scope |
Benzodiazepines with specific substitutions |
| Therapeutic use |
Anti-anxiety, sedatives, tranquilizers |
| Patent family |
Family includes filings in Europe, Canada, and Japan |
| Related patents |
U.S. Patents 3,584,126; 3,649,257 (another early benzodiazepine patent) |
| Patent expiration |
1989, engine of generic entry |
Key Takeaways
- U.S. Patent 3,646,207 defines a broad class of benzodiazepines, including diazepam.
- It claims both the compounds and their therapeutic applications.
- The patent expired in 1989, leading to widespread generic competition.
- The current patent landscape focuses on formulations and derivatives with newer patents, not on the original compounds.
- The underlying chemical innovations are not protected, which limits patentability for new benzodiazepines based solely on this scope.
5 FAQs
1. Does U.S. Patent 3,646,207 still provide market exclusivity today?
No. The patent expired in 1989, allowing generic manufacturers to produce benzodiazepines covered by the patent.
2. Can new benzodiazepines be patented based on this patent?
No. The patent’s chemical scope is expired, but new compounds can be patentable if they are structurally novel and non-obvious beyond the scope of this patent.
3. How does this patent influence current benzodiazepine patenting strategies?
It primarily affects the patent landscape by establishing foundational claims, but modern patent strategies focus on novel formulations, delivery systems, or derivatives.
4. Are there still active patents related to benzodiazepines?
Most original patents are expired; current activity involves patents on formulations and delivery methods rather than the core chemical structures.
5. How comprehensive was U.S. Patent 3,646,207 in covering benzodiazepines?
It was broad for its time, covering various substituted benzodiazepines, but subsequent patents have extended or modified the scope for newer developments.
References
[1] U.S. Patent and Trademark Office. Patent 3,646,207. https://patents.google.com/patent/US3646207A/en
[2] Katzung, B. G., & Trevor, A. J. (2018). Basic and Clinical Pharmacology (14th ed.). McGraw-Hill Education.
[3] Wermuth, C. G., et al. (2011). The Practice of Medicinal Chemistry. Elsevier.
More… ↓
⤷ Start Trial
|
